問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
許志堅
下載
2025-11-01 - 2033-12-31
Condition/Disease
Locally advanced unresectable or metastatic HER2-overexpressing non-squamous non-small cell lung cancer
Test Drug
Trastuzumab Deruxtecan(AZD4552 DS-8201A)
Participate Sites9Sites
Recruiting9Sites
2019-11-01 - 2026-12-31
Participate Sites6Sites
Recruiting6Sites
2023-07-01 - 2028-12-31
Participate Sites4Sites
Recruiting4Sites
2021-10-01 - 2026-12-31
Participate Sites8Sites
Recruiting8Sites
2021-02-28 - 2029-12-31
Participate Sites7Sites
Recruiting7Sites
2022-09-15 - 2026-09-30
2022-04-01 - 2026-03-31
2023-02-01 - 2026-12-31
2024-01-01 - 2030-06-30
Participate Sites10Sites
Recruiting10Sites
2025-06-01 - 2029-06-30
全部
